{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:12:14Z","timestamp":1761174734012,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":3652,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1111\/j.1469-0691.2004.01023.x","type":"journal-article","created":{"date-parts":[[2004,12,3]],"date-time":"2004-12-03T12:10:54Z","timestamp":1102075854000},"page":"1067-1074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon"],"prefix":"10.1016","volume":"10","author":[{"given":"A.","family":"Arizcorreta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Brun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fern\u00e1ndez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garc\u00eda Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"P\u00e9rez-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Gir\u00f3n-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2004.01023.x_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00002030-200204120-00001","article-title":"Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel","volume":"16","author":"Soriano","year":"2002","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/367643","article-title":"Progression to liver fibrosis and cirrhosis of chronic hepatitis C in HIV co-infected patients","volume":"36","author":"Martinez-Sierra","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/BF01691375","article-title":"Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally-acquired hepatitis C","volume":"14","author":"Sanchez-Quijano","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/jhep.2001.29201","article-title":"The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long term retrospective cohort study","volume":"34","author":"Di Martino","year":"2001","journal-title":"Hepatology"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1086\/376971","article-title":"Hematologic disorders associated with hepatitis C virus infection and their management","volume":"37","author":"Dieterich","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib10","first-page":"301","article-title":"A comparative trial of recombinant interferon alpha 2A versus alpha 2 beta on myelosuppression in healthy adult volunteers","volume":"43","author":"Wong","year":"1996","journal-title":"Hepatogastroenterology"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/gut.47.5.694","article-title":"Safety and efficacy of interferon\u2013ribavirin combination therapy in HCV\u2013HIV coinfected subjects: an early report","volume":"47","author":"Zylberberg","year":"2000","journal-title":"Gut"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00002030-200005050-00010","article-title":"Efficacy and safety of combination therapy with interferon-\u03b12b and ribavirin for chronic hepatitis C in HIV-infected patients","volume":"14","author":"Landau","year":"2000","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/00002030-200109280-00006","article-title":"Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa 2b and ribavirin","volume":"15","author":"Nasti","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00002030-200111090-00010","article-title":"Long term efficacy of combination therapy with interferon alpha2b and ribavirin for severe chronic hepatitis C in HIV-infected patients","volume":"15","author":"Landau","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/jhep.2001.29130","article-title":"Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders","volume":"34","author":"Sauleda","year":"2001","journal-title":"Hepatology"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00002030-199904010-00002","article-title":"Management of chronic hepatitis C in HIV-infected patients","volume":"13","author":"Soriano","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib18","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1001\/jama.283.3.381","article-title":"Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel","volume":"283","author":"Carpenter","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/gast.1996.v110.pm8536854","article-title":"Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection","volume":"110","author":"Prati","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib22","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood.V84.12.4142.bloodjournal84124142","article-title":"Regulation of cytokine expression by interferon-\u03b1 in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist","volume":"84","author":"Aman","year":"1994","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2004.01023.x_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428199609074370","article-title":"Influence of interferon-\u03b1 on cytokine expression by the bone marrow microenvironment. Impact on treatment of myeloproliferative disorders","volume":"22","author":"Peschel","year":"1996","journal-title":"Leukemia Lymphoma"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V70.4.1173.1173","article-title":"Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells","volume":"70","author":"Ganser","year":"1987","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib25","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/00002030-199411000-00016","article-title":"CD4+ lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C","volume":"8","author":"Soriano","year":"1994","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchinson","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2893.2000.00243.x","article-title":"Interferon and ribavirin versus interferon alone in the re-treatment of chronic hepatitis C patients who relapsed or did not respond to interferon alone","volume":"7","author":"Cummings","year":"2000","journal-title":"J Viral Hepatol"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1310\/H2CF-3KNA-Q3Y9-C3G1","article-title":"Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference","volume":"3","author":"Garc\u00eda-Samaniego","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-138-3-200302040-00012","article-title":"Hepatitis C in the HIV-infected person","volume":"138","author":"Sulkowski","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/AAC.41.6.1231","article-title":". Effects of drugs on 2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydrothymidine phosphorylation in vitro","volume":"41","author":"Hoggard","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.01023.x_bib35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"35","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2004.01023.x_bib36","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14638489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14638489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:18:24Z","timestamp":1761117504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14638489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S1198743X14638489"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.01023.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.01023.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}